Suppr超能文献

球周注射曲安奈德联合或不联合局部光凝治疗轻度糖尿病性黄斑水肿的随机试验:一项初步研究

Randomized trial of peribulbar triamcinolone acetonide with and without focal photocoagulation for mild diabetic macular edema: a pilot study.

作者信息

Chew E, Strauber S, Beck R, Aiello L P, Antoszyk A, Bressler N, Browning D, Danis R, Fan J, Flaxel C, Friedman S, Glassman A, Kollman C, Lazarus H

出版信息

Ophthalmology. 2007 Jun;114(6):1190-6. doi: 10.1016/j.ophtha.2007.02.010.

Abstract

OBJECTIVE

To provide pilot data on the safety and efficacy of anterior and posterior sub-Tenon injections of triamcinolone either alone or in combination with focal photocoagulation in the treatment of mild diabetic macular edema (DME).

DESIGN

Prospective, phase II, multicenter, randomized clinical trial.

PARTICIPANTS

One hundred nine patients (129 eyes) with mild DME and visual acuity 20/40 or better.

METHODS

The participants were assigned randomly to receive either focal photocoagulation (n = 38), a 20-mg anterior sub-Tenon injection of triamcinolone (n = 23), a 20-mg anterior sub-Tenon injection followed by focal photocoagulation after 4 weeks (n = 25), a 40-mg posterior sub-Tenon injection of triamcinolone (n = 21), or a 40-mg posterior sub-Tenon injection followed by focal photocoagulation after 4 weeks (n = 22). Follow-up visits were performed at 4, 8, 17, and 34 weeks.

MAIN OUTCOME MEASURES

Change in visual acuity and retinal thickness measured with optical coherence tomography (OCT).

RESULTS

At baseline, mean visual acuity in the study eyes was 20/25 and mean OCT central subfield thickness was 328 mum. Changes in retinal thickening and in visual acuity were not significantly different among the 5 groups at 34 weeks (P = 0.46 and P = 0.94, respectively). There was a suggestion of a greater proportion of eyes having a central subfield thickness less than 250 mum at 17 weeks when the peribulbar triamcinolone was combined with focal photocoagulation. Elevated intraocular pressure and ptosis were adverse effects attributable to the injections.

CONCLUSIONS

In cases of DME with good visual acuity, peribulbar triamcinolone, with or without focal photocoagulation, is unlikely to be of substantial benefit. Based on these results, a phase III trial to evaluate the benefit of these treatments for mild DME is not warranted.

摘要

目的

提供关于单独或联合局部光凝的曲安奈德前后Tenon囊下注射治疗轻度糖尿病性黄斑水肿(DME)安全性和有效性的初步数据。

设计

前瞻性、II期、多中心、随机临床试验。

参与者

109例(129只眼)轻度DME且视力为20/40或更好的患者。

方法

参与者被随机分配接受局部光凝(n = 38)、20mg曲安奈德Tenon囊下前注射(n = 23)、20mg曲安奈德Tenon囊下前注射4周后再行局部光凝(n = 25)、40mg曲安奈德Tenon囊下后注射(n = 21)或40mg曲安奈德Tenon囊下后注射4周后再行局部光凝(n = 22)。在第4、8、17和34周进行随访。主要观察指标:用光学相干断层扫描(OCT)测量的视力和视网膜厚度变化。

结果

基线时,研究眼的平均视力为20/25,OCT中心子野平均厚度为328μm。在34周时,5组之间视网膜增厚和视力变化无显著差异(分别为P = 0.46和P = 0.94)。当球周曲安奈德联合局部光凝时,在17周时有更多比例的眼中心子野厚度小于250μm的趋势。眼内压升高和上睑下垂是注射引起的不良反应。

结论

在视力良好的DME病例中,球周曲安奈德无论是否联合局部光凝,都不太可能有实质性益处。基于这些结果,没有必要进行III期试验来评估这些治疗对轻度DME的益处。

相似文献

2
A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema.
Ophthalmology. 2008 Sep;115(9):1447-9, 1449.e1-10. doi: 10.1016/j.ophtha.2008.06.015. Epub 2008 Jul 26.
3
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema.
Ophthalmology. 2010 Jun;117(6):1064-1077.e35. doi: 10.1016/j.ophtha.2010.02.031. Epub 2010 Apr 28.
4
Posterior sub-Tenon injection of triamcinolone acetonide as pretreatment for focal laser photocoagulation in diabetic macular edema patients.
Jpn J Ophthalmol. 2008 Jul-Aug;52(4):265-268. doi: 10.1007/s10384-008-0549-3. Epub 2008 Sep 5.
10

引用本文的文献

2
Comparing the efficacy of glucocorticoids and anti-VEGF in treating diabetic macular edema: systematic review and comprehensive analysis.
Front Endocrinol (Lausanne). 2024 Mar 22;15:1342530. doi: 10.3389/fendo.2024.1342530. eCollection 2024.
3
Current and Novel Therapeutic Approaches for Treatment of Diabetic Macular Edema.
Cells. 2022 Jun 17;11(12):1950. doi: 10.3390/cells11121950.
6
Corticosteroids for Diabetic Macular Edema.
Taiwan J Ophthalmol. 2019 Dec 13;9(4):233-242. doi: 10.4103/tjo.tjo_68_19. eCollection 2019 Oct-Dec.
7
Intraocular pressure elevation after subtenon triamcinolone acetonide injection; Multicentre retrospective cohort study in Japan.
PLoS One. 2019 Dec 5;14(12):e0226118. doi: 10.1371/journal.pone.0226118. eCollection 2019.
10
Diabetic macular edema: Evidence-based management.
Indian J Ophthalmol. 2018 Dec;66(12):1736-1750. doi: 10.4103/ijo.IJO_1240_18.

本文引用的文献

1
Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema.
Ophthalmology. 2007 Mar;114(3):525-36. doi: 10.1016/j.ophtha.2006.06.052. Epub 2006 Nov 21.
2
Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.
Am J Ophthalmol. 2006 Dec;142(6):961-9. doi: 10.1016/j.ajo.2006.06.068. Epub 2006 Aug 2.
4
Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
Ophthalmology. 2006 Dec;113(12):2221-30. doi: 10.1016/j.ophtha.2006.07.032. Epub 2006 Sep 20.
5
Posterior subtenon and intravitreal triamcinolone acetonide for diabetic macular edema.
J Diabetes Complications. 2006 Jul-Aug;20(4):246-51. doi: 10.1016/j.jdiacomp.2005.06.015.
6
Posterior sub-tenon triamcinolone for refractory diabetic macular edema: a randomized clinical trial.
Eur J Ophthalmol. 2005 Nov-Dec;15(6):746-50. doi: 10.1177/112067210501500614.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验